3-MeO-PCE

Relative contraindication in individuals with hypertension, coronary artery disease, arrhythmias, or heart failure. Cardiovascular stress is a class effect of arylcyclohexylamines.

Any condition impairing respiratory function (COPD, severe asthma, sleep apnea) increases overdose risk. Respiratory depression confirmed as cause of death in polydrug case involving 3-MeO-PCE.

Contraindicated in individuals with epilepsy or seizure disorders. Also contraindicated in combination with other medications that lower seizure threshold.

Strongly contraindicated in individuals with personal or family history of psychotic disorders including schizophrenia and schizoaffective disorder. The dual NMDA antagonism and serotonergic potentiation creates an elevated psychotomimetic profile relative to other dissociatives.

Strongly contraindicated. 3-MeO-PCE carries higher mania risk than most dissociatives due to its potent serotonin reuptake inhibition layered onto NMDA antagonism.

Relative contraindication. Hepatic metabolism confirmed (Xu et al. 2024) but specific CYP enzymes not identified. Dose adjustment cannot be recommended without pharmacokinetic data.

No reproductive toxicity data exist for 3-MeO-PCE. Contraindicated on a precautionary basis given NMDA receptor involvement in neurodevelopment and absence of safety data.

Absolutely contraindicated with MAOIs. Strongly contraindicated with SSRIs and SNRIs. Fatal case involving SERT-inhibiting arylcyclohexylamine (N-ethyldeschloroketamine) combined with venlafaxine reported.